Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Phase III data support use of NGX-4010 in postherpetic neuralgia

Jan. 23, 2009

Neurologix initiates phase II clinical trial of gene transfer therapy for Parkinson's disease

Jan. 23, 2009

Novel calcitonin gene-related peptide (CGRP) receptor antagonists disclosed by Merck & Co.

Jan. 23, 2009

Vitamin effect on homocystine levels does not affect Abeta levels in stroke patients

Jan. 22, 2009

Merck & Co. divulge new gamma-secretase modulators for Alzheimer's disease

Jan. 22, 2009

AVI reports positive results from phase I trial of AVI-4658 for DMD

Jan. 22, 2009

Parkinson's disease drug Trerief obtains marketing approval in Japan

Jan. 22, 2009

Alexza initiates phase IIb clinical trial of Staccato loxapine in migraine

Jan. 22, 2009

Novel mGluR5 receptor modulators with antipsychotic properties developed at GSK

Jan. 22, 2009

Recent Roche patent reports new antipsychotic tachykinin NK3 receptor antagonists

Jan. 22, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 8, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.